FoRx Therapeutics is a privately held clinical-stage biotechnology company pioneering precision therapeutics targeting the DNA Damage Response in treatment-resistant cancers. Its lead product ...
Sofio uses patented magnetohydrodynamics (MHD) to draw a micro-sample of interstitial fluid through skin, where glucose is measured using established glucose oxidase enzyme chemistry, the same method ...
Paris, France and London, United Kingdom (18 December 2025) – EssilorLuxottica and Burberry today announced the renewal of their licensing agreement for the development, production and global ...
The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, reports that it has suffered ...
Strengthens DSR patent protection based upon extensive clinical and pre-clinical experience Data published in European Journal of Heart Failure supports DSR as breakthrough in treatment of cardiorenal ...
InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug ...
Three of the biotech industry’s trusted advisory firms: KreaMedica, Venture Valuation, and Lacerta Bio, today announced the release of The First-Time Biotech CEO Playbook, a practical guide designed ...
Sapu BioScience has been developing TGFB2-targeted antisense therapeutics, establishing one of the deepest proprietary knowledge bases around this pathway in oncology. That work has generated a broad ...
Singlera Genomics, a company focused on the application of novel DNA methylation technologies to genetic diagnosis, with their partner Breakthrough Genomics, a leader in the clinical analysis of ...
Notably, the company completed its End-of-Phase 2 (EOP2) interactions with the U.S. Food and Drug Administration (FDA) and received scientific advice from the European Medicines Agency (EMA).
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it has ...
Lifeward selected Verita as its partner in these targeted regions to integrate ReWalk into their multi-modal treatment methodologies for people living with neurological and spinal cord injuries. Today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback